DBV Technologies Stock Soars 5.6% Midday, Surpassing 3.50 Euros

Continued Momentum in Stock Performance

Thursday's progress is part of a remarkable upward momentum, with the stock already having gained 6.44% on Wednesday, 9.06% on Tuesday, and 9.16% on Monday. Over the week, DBV Technologies now shows a surge of 54.19%, while its quarterly performance reaches 121.8%. The annual surge peaks at 435.2%, placing the stock among the highest gains in the Paris market in 2025, while the CAC 40 has only increased by about 8% over the same period. This spectacular rise occurs as investors position themselves ahead of the imminent release of preliminary results from the phase 3 VITESSE trial, which evaluates the efficacy of the Viaskin Peanut patch in children allergic to peanuts. The phase 3 VITESSE trial assesses the efficacy and safety of the Viaskin Peanut patch in 654 subjects aged 4 to 7 years allergic to peanuts, involving individuals across 86 sites in the United States, Canada, Europe, the United Kingdom, and Australia. These results, expected before the end of December, represent a crucial milestone that could condition the filing of a marketing authorization application with the FDA.

Technical Analysis of the Stock

Technically, the stock is now trading well above its 50-day moving average, set at 2.54 euros, confirming the strength of the short-term bullish trend. This growing gap of nearly 38% between the stock price and the moving average signals that buyers are clearly dominating the market. The stock has also surpassed its major resistance set at 3.32 euros, thereby opening up new technical progression space. The RSI is now at 73, a level that indicates entry into an overbought zone beyond the 70 threshold. This indicator reflects a very marked enthusiasm from investors and suggests that a technical pause or consolidation could occur in the short term. The MACD shows a very positive configuration with a histogram at 0.10, the MACD line (0.08) having significantly crossed its signal line (-0.02). This bullish crossover confirms the strengthening of the buying momentum and validates the continuation of the upward trend. Volatility remains high at 27.41% over a month, characteristic of biotechs awaiting crucial clinical results. The support is now at 2.26 euros, a level that should contain any potential pullback.

DBV Technologies' Financial and Market Position

DBV Technologies, listed in Paris and on the Nasdaq, develops treatments for food allergies through its epicutaneous immunotherapy platform Viaskin, which allows the administration of antigens through the skin without ingestion. DBV Technologies closed the third quarter of 2025 with a cash balance and cash equivalents of 69.8 million dollars, enabling the funding of activities until the third quarter of 2026. This financial visibility reassures investors about the company's ability to carry out its clinical and regulatory projects. With a negative beta of -0.25, the stock shows an inverse correlation with the market, explaining its trajectory completely independent of the CAC 40. This characteristic reflects the speculative profile of the stock, whose movements are more closely linked to clinical and regulatory catalysts than to general market trends. In this context of anticipation, the continuous progression of the stock reflects the optimism of investors regarding the prospects of the Viaskin Peanut patch. Crossing the threshold of 3.50 euros marks a major symbolic and technical milestone, which could pave the way for further gains if the clinical results prove positive by the end of the month.